A prospective, longitudinal, descriptive study was conducted from January 2016 to January 2018 to detect nerve dysfunction after hip arthroscopy. A total of 110 patients were included. Twenty-four hours after surgery, 62.7% reported symptoms of abnormal sensation at least in one area. Nerve dysfunction after HA was more common than has been reported in the literature within large populations. Traction time was a significant factor in the development of perineal nerve dysfunction.
Here Bronte, et al. retrospectively analyzed ER, PgR, and AR expression on a case series of 159 specimens of primary BC samples by using immunohistochemistry and 89 patients of these had luminal tumors for which AR and ER expression and survival data were available. For twenty-four patients both primary and metastatic tumors were available. In conclusion, these findings indicate that a prospective study is needed to better clarify the role of AR/ER ratio in different BC settings (i.e., adjuvant and metastatic). The relation between AR and PgR has to be better understood even if our findings suggest that a high AR/PgR ratio in luminal tumors is prognostically unfavorable and could be used as an additional risk-stratification marker.
Researchers at Montefiore Medical Center observed that extracorporeal membrane oxygenation (ECMO) is gaining ground as a tool to rescue and manage adult patients with severe cardiac or respiratory failure who would otherwise likely die. Between 2006 and 2011, the use of ECMO has increased by more than 400%.
In a paper published in the journal Science Advances, a group of researchers describes the technique they developed for detecting the early stages of Alzheimer's disease in patients who have yet to exhibit symptoms. They report that their technique reliably distinguishes between diagnosed patients and those in a control group.
A new agent that can inhibit platelet aggregation for the treatment of acute ischemic stroke without causing bleeding has shown promising results in a recent study. The approach targets the GPVI protein on platelets, a mechanism completely different from those of any currently available antiplatelet drugs.
Practicing ADA member dentists recently reported which clinical interventions they believe require adjunct antimicrobial treatment, their preferred antibiotic to use in immunocompetent adults, and more. These dentists, from the ADA Clinical Evaluators (ACE) Panel, note that the key to successfully managing an infection of endodontic origin is proper root canal debridement accompanied by disinfection and abscess drainage when swelling is present.
The first fibroblast growth factor receptor (FGFR) kinase inhibitor, erdafitinib, was approved by the FDA for adults with locally advanced bladder cancer with a FGFR3 mutation or FGFR2 fusion who have progressed despite platinum-based chemotherapy.
Dr, Socinski discusses new applications for immunotherapy in the treatment of patients with non–small cell lung cancer. There are 2 basic elements that providers have to get right - one is the diagnosis, which includes histology and PD-L1 status, or molecular status in stage IV disease. The second important factor is the disease stage. Socinski said that researchers are enthusiastic about the progress with these therapies in stage IV disease and are hopeful these advances can extend into earlier settings.
According to a new study by Washington University School of Medicine in St. Louis, the new rules for reimbursement are capable of providing a little relief to safety-net hospitals by shifting the burden towards wealthier patient populations. The new rules divide hospitals into five groups based on the proportion of their Medicare patients who are also enrolled in Medicaid.
This study will serve as a pilot study to determine the efficacy and safety of two novel oral agents (clonidine, naltrexone) in the treatment of chronic, non-experimentally induced itch in atopic dermatitis. In this study, eight subjects with symptomatic atopic dermatitis will be recruited and treated with either oral clonidine (four subjects) or oral naltrexone (four subjects). Disease burden will be evaluated before and after 4 weeks of treatment through reporting of subjective symptomatology via surveys/questionnaire, neurometer study, and clinical assessment.